Skip to search formSkip to main contentSkip to account menu

toceranib phosphate

National Institutes of Health

Related topics

Related topics

7 relations

Broader (3)

IndolesPyrrolestoceranib

Narrower (2)

PalladiaSU 11654
Receptor Tyrosine Kinase Inhibitiontoceranib phosphate 15 MG Oral Tablet [Palladia]

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Assessment of postoperative adjuvant treatment using toceranib phosphate against adenocarcinoma in dogs
Abstract Background Toceranib phosphate (TOC) could be made widely available for treating tumors in dogs if evidence shows that… 
Review
2019
Review
2019
Response and outcome following toceranib phosphate treatment for stage four anal sac apocrine gland adenocarcinoma in dogs: 15 cases (2013-2017).
OBJECTIVE To assess response and outcome in dogs with stage 4 anal sac apocrine gland adenocarcinoma (ASAGA) treated with… 
2018
2018
Safety evaluation of combination carboplatin and toceranib phosphate (Palladia) in tumour‐bearing dogs: A phase I dose finding study
Combining conventional cytotoxic maximum tolerated dose (MTD) chemotherapy with low-dose metronomic and/or anti-angiogenic agents… 
2016
2016
Safety evaluation of combination CCNU and continuous toceranib phosphate (Palladia(®) ) in tumour-bearing dogs: a phase I dose-finding study.
While maintaining a standard toceranib dosage [2.75 mg kg(-1) , PO, every other day (EOD)], three dose-escalating CCNU cohorts up… 
2016
2016
A pilot study of toceranib/vinblastine therapy for canine transitional cell carcinoma
BackgroundEffective therapies for transitional cell carcinoma (TCC) are limited, with objective response rates to most… 
2016
2016
Effects of Toceranib Phosphate on Systolic Blood Pressure and Proteinuria in Dogs
Background Systemic hypertension and proteinuria are established adverse effects of tyrosine kinase inhibitor treatment in people… 
2015
2015
Pulse‐Administered Toceranib Phosphate Plus Lomustine for Treatment of Unresectable Mast Cell Tumors in Dogs
Background Nonresectable mast cell tumors (MCT) in dogs remain a therapeutic challenge, and investigation of novel combination… 
2012
2012
Preliminary evaluation of serial (18) FDG-PET/CT to assess response to toceranib phosphate therapy in canine cancer.
Palladia(TM) (toceranib phosphate-Pfizer Animal Health) is a novel orally administered receptor tyrosine kinase inhibitor (TKI… 
2010
2010
Pharmacokinetic properties of toceranib phosphate (Palladia, SU11654), a novel tyrosine kinase inhibitor, in laboratory dogs and dogs with mast cell tumors.
Toceranib phosphate (Palladia, SU11654), an oral tyrosine-kinase inhibitor, is under investigation for the treatment of mast cell… 
Review
2010
Review
2010
Distribution, metabolism, and excretion of toceranib phosphate (Palladia, SU11654), a novel tyrosine kinase inhibitor, in dogs.
Toceranib phosphate (Palladia, SU11654), a multireceptor tyrosine kinase inhibitor with anti-tumor and anti-angiogenic activity… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)